Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 57.82 USD -2.99% Market Closed
Market Cap: 116.4B USD

Profitability Summary

Bristol-Myers Squibb Co's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Bristol-Myers Squibb Co

Revenue
48.3B USD
Cost of Revenue
-11.9B USD
Gross Profit
36.4B USD
Operating Expenses
-24.8B USD
Operating Income
11.5B USD
Other Expenses
-20.5B USD
Net Income
-8.9B USD

Margins Comparison
Bristol-Myers Squibb Co Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
US
Bristol-Myers Squibb Co
NYSE:BMY
114.7B USD
75%
24%
-19%
US
Eli Lilly and Co
NYSE:LLY
747.7B USD
81%
38%
24%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
384.7B USD
69%
26%
16%
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK
85%
48%
35%
CH
Roche Holding AG
SIX:ROG
209.5B CHF
73%
32%
20%
UK
AstraZeneca PLC
LSE:AZN
170.8B GBP
82%
23%
13%
CH
Novartis AG
SIX:NOVN
186.8B CHF
75%
32%
23%
US
Merck & Co Inc
NYSE:MRK
218.7B USD
81%
36%
27%
IE
Endo International PLC
LSE:0Y5F
162.4B USD
68%
11%
-126%
US
Pfizer Inc
NYSE:PFE
137.6B USD
74%
25%
13%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Bristol-Myers Squibb Co Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Bristol-Myers Squibb Co
NYSE:BMY
114.7B USD
-39%
-10%
16%
16%
US
Eli Lilly and Co
NYSE:LLY
747.7B USD
85%
15%
39%
22%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
384.7B USD
20%
8%
19%
14%
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK
81%
26%
71%
33%
CH
Roche Holding AG
SIX:ROG
209.5B CHF
40%
13%
29%
22%
UK
AstraZeneca PLC
LSE:AZN
170.8B GBP
18%
7%
17%
14%
CH
Novartis AG
SIX:NOVN
186.8B CHF
27%
12%
23%
17%
US
Merck & Co Inc
NYSE:MRK
218.7B USD
42%
15%
28%
21%
IE
Endo International PLC
LSE:0Y5F
162.4B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
137.6B USD
9%
4%
9%
8%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less